MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - October 16, 2012) - MorphoSys AG /
AbD Serotec Licenses HuCAL Antibodies to DiaSorin for Use in Clinical
Assays for Infectious Disease Testing. Processed and transmitted by Thomson
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
DiaSorin S.p.A., a worldwide provider of specialty assays, has taken a
for two recombinant HuCAL antibodies. The antibodies, which were made
Serotec, MorphoSys's division for research and diagnostic antibodies,
recombinant controls for two marketed infectious disease assays. AbD
will receive license fees and royalties on sales of kits
antibodies. Further financial details were not disclosed.
The collaboration between DiaSorin and AbD Serotec brings together
broad expertise in the development, manufacturing and
immunodiagnostic test systems and AbD Serotec's leading recombinant
antibody generation technology. AbD Serotec has generated two
antibodies in the IgM format, which DiaSorin is implementing into
diagnostic tests for Measles IgM and Mumps IgM. The introduction of the
LIAISON® Measles IgM and LIAISON® Mumps IgM assays provides
the first and
only fully automated immunoassays on the diagnostic market for the
determination of the immunity status of patients to measles and mumps
"Today's news is another example of AbD Serotec's ability to offer
solutions for diagnostic companies in the quickest possible time using the
technology", commented Dieter Feger, Senior Vice President and
MorphoSys's AbD Serotec Division. "Recombinant control antibodies based
HuCAL technology support the provision of accurate results through
diagnostic assay management."
MorphoSys developed HuCAL, the most successful antibody library
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of
antibodies, one of the fastest-growing drug classes in human
company's AbD Serotec unit uses HuCAL and other antibody
generate superior monoclonal antibodies for research and
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
and Ylanthia® and 100 billion high potentials® are registered
Slonomics® is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
LIAISON® is a registered trademark of DiaSorin S.p.A.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE